NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $100.96 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IHE alerts:Sign Up Key Stats Today's Range$98.63▼$100.9650-Day Range$84.82▼$100.9652-Week Range$64.94▼$100.96Volume884,595 shsAverage Volume110,826 shsMarket Capitalization$1.17 billionAssets Under Management$1.22 billionDividend Yield1.45%Net Expense Ratio0.39%Aggregate RatingModerate Buy ETF Overview iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors. Read More iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.39%0.56%0.57%0.51%0.53%Other Expenses0.00%0.47%0.55%0.58%0.55%Total Expense0.39%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.39%0.59%0.63%0.58%0.60% Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IHE ETF News HeadlinesiShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 12-Month High - Should You Buy?June 30, 2026 | americanbankingnews.comiShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF ReturnsJune 10, 2026 | fool.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 5 at 1:00 AM | Stansberry Research (Ad)Pharma stocks are showing strength. Charts predict this name could break out nextJune 8, 2026 | cnbc.comUS FDA to review AI-based tool to predict drug-related liver damageJune 3, 2026 | reuters.comGLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.May 27, 2026 | fool.comSee More Headlines IHE ETF - Frequently Asked Questions How have IHE shares performed this year? iShares U.S. Pharmaceuticals ETF's stock was trading at $84.83 on January 1st, 2026. Since then, IHE shares have increased by 19.0% and is now trading at $100.96. When did iShares U.S. Pharmaceuticals ETF's stock split? Shares of iShares U.S. Pharmaceuticals ETF split on Thursday, March 7th 2024.The 3-1 split was announced on Thursday, March 7th 2024. The newly created shares were distributed to shareholders after the market closes on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares U.S. Pharmaceuticals ETF's major shareholders? iShares U.S. Pharmaceuticals ETF's top institutional investors include CX Institutional. How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Visa (V), Adobe (ADBE), Lam Research (LRCX) and Advanced Micro Devices (AMD). Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings60 Fund Statistics Assets Under Management$1.22 billion Average Daily Volume$183.33 thousand Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume4 Put Options0 Call Options4 Short Interest647,772 shs Miscellaneous Outstanding Shares11,550,000Beta0.49 Creation Unit50,000 Creation Fee$306.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 IHE HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 21.90%Johnson & Johnson (NYSE:JNJ)Holding Weight: 21.90%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 4.44%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.44%Pfizer (NYSE:PFE)Holding Weight: 4.43%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 4.38%Viatris (NASDAQ:VTRS)Holding Weight: 4.38%Zoetis (NYSE:ZTS)Holding Weight: 4.22%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.47%Elanco Animal Health (NYSE:ELAN)Holding Weight: 2.92%Full Holdings DetailsIHE Sector ExposureIHE Industry Exposure This page (NYSEARCA:IHE) was last updated on 7/5/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
